文献速递分子诊断临床生化

快速筛查CYP24A1致病性变异为特发性婴儿高钙血症分子检测开辟道路

A rapid screening of a recurrent CYP24A1 pathogenic variant opens the way to molecular testing for Idiopathic Infantile Hypercalcemia (IIH).
PubMed 文献 · Clin Chim Acta · 2018-03-21

本研究基于高分辨率熔解曲线分析(HRMA)设计了一种快速检测CYP24A1基因c.428_430delAAG(p.Glu143del)变异的方法,该变异与特发性婴儿高钙血症(IIH)相关。结果显示HRMA能通过熔解曲线形状和熔解温度(Tm)区分杂合与 homozygous 基因型,杂合样本显示典型熔解曲线,纯合样本显示特异性Tm偏移。结论认为该方法可用于临床分子诊断,为IIH的分子分析、改善药物治疗策略及降低复发结石和肾钙化症风险提供帮助。

要点

  • HRMA可快速检测CYP24A1 c.428_430delAAG变异,区分杂合与纯合基因型。
  • 该变异与特发性婴儿高钙血症(IIH)及成人肾结石病相关。
  • 方法有望用于IIH的临床分子诊断,指导治疗并降低复发风险。

核心结论

  • HRMA可用于CYP24A1 c.428_430delAAG变异的明确基因分型,适用于临床分子诊断。

研究设计与样本

  • 设计基于高分辨率熔解曲线分析(HRMA)的快速CYP24A1基因检测方法,用于检测c.428_430delAAG(p.Glu143del)变异。

主要发现

  • HRMA通过评估熔解曲线形状和熔解温度(Tm)识别c.428_430delAAG基因型。
  • 杂合样本显示典型熔解曲线,纯合样本显示特异性Tm偏移。

临床怎么用

  • 该方法可用于IIH诊断中的CYP24A1基因分子分析,辅助改善药物治疗策略并降低复发结石和肾钙化症恶化风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Loss-of-function mutations in cytochrome P450 family 24 subfamily A member 1 (CYP24A1) gene are associated with Idiopathic Infantile Hypercalcemia (IIH) and adult kidney stone disease. The enzyme deficiency leads to an impaired vitamin D catabolism pathway, resulting in a syndrome characterized by recurrent hypercalcemia, hypercalciuria and suppressed parathyroid hormone (PTH) levels. In these patients, the genetic evaluation of CYP24A1 is an important diagnostic tool, allowing the definitive diagnosis of IIH. METHODS: A rapid CYP24A1 gene testing based on High Resolution Melting Analysis (HRMA) was designed in order to detect the CYP24A1 c.428_430delAAG (p.Glu143del), a recurrent IIH-associated variant. RESULTS: HRMA method was able to identify c.428_430delAAG genotypes evaluating melting curve shape and melting temperature (Tm). Heterozygous samples exhibited a typical melting profile while homozygous samples showed a specific Tm shift. CONCLUSIONS: We provide evidence about application of HRMA in unambiguous genotyping of the CYP24A1 c.428_430delAAG variant, making this method useful in clinical molecular diagnostics. This approach opens the way to a helpful molecular analysis of CYP24A1 gene in IIH diagnosis, to an improved pharmacological treatment strategy and to a reduced risk of recurrent stones and worsening nephrocalcinosis.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. De Paolis E, Minucci A, De Bonis M, et al. A rapid screening of a recurrent CYP24A1 pathogenic variant opens the way to molecular testing for Idiopathic Infantile Hypercalcemia (IIH). Clin Chim Acta. 2018. PMID: 29574006. doi:10.1016/j.cca.2018.03.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。